Targeting Leishmania major parasite with peptides derived from a combinatorial phage display library

Acta Tropica

Volumn 159, Issue , 2016, Pages 11-19

  Rhaiem, Rafik Ben ^a   Houimel, Mehdi ^a  

^a PASTEUR INSTITUTE OF TUNIS   (Tunisia)

Author keywords

Gp63; Leishmania major; Molecular docking; Peptide; Phage display; Protection

Indexed keywords

DNA; PEPTIDE DERIVATIVE; PEPTIDE P1; PEPTIDE P2; PEPTIDE P3; PROTEIN GP63; PROTEINASE; UNCLASSIFIED DRUG; PEPTIDE;

AMINO ACID; ENDOPARASITE; LEISHMANIASIS; MOLECULAR ANALYSIS; PARASITIC DISEASE; PROTEIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIOPHAGE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOOT PAD; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA MAJOR; LEISHMANIASIS; MOLECULAR DOCKING; MONOCYTE; MOUSE; NONHUMAN; PHAGE DISPLAY; POLYMERASE CHAIN REACTION; PROMASTIGOTE; SKIN DEFECT; WESTERN BLOTTING; ANIMAL; GENE LIBRARY; GENETICS; IMMUNOLOGY; MACROPHAGE; NUCLEOTIDE SEQUENCE; PARASITOLOGY; SKIN LEISHMANIASIS;

FILAMENTOUS BACTERIOPHAGE; LEISHMANIA MAJOR; MUS; PROTOZOA;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; GENE LIBRARY; HUMANS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MACROPHAGES; MICE; MICE, INBRED BALB C; MOLECULAR DOCKING SIMULATION; PEPTIDES;

EID: 84961770607     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2016.03.018     Document Type: Article

References (32)

1. Ashutosh G.S., Ramesh S., Goyal N. Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening. Antimicrob. Agents Chemother. 2005, 49:3776-3783.
2. Berman J. Clinical status of agents being developed for leishmaniasis. Expert. Opin. Investig. Drugs 2005, 14:1337-1346.
3. Bishop-Hurley S.L., Schmidt F.J., Erwin A.L., Smith A.L. Peptides selected forbinding to a virulent strain of Haemophilus influenzae by phage display arebactericidal. Antimicrob. Agents Chemother. 2005, 49(7):2972-2978.
4. Bouvier J., Schneider P., Etges R. Leishmanolysin: surface metalloproteinase of Leishmania. Methods Enzymol. 1995, 248:614-633.
5. Brittingham A., Morrison C.J., McMaster W.R., McGwire B.S., Chang K.P., Mosser D.M. Role of the Leishmania surface protease gp63 in complement fixation, cell adhesion, and resistance to complement-mediated lysis. J. Immunol. 1995, 155(6):3102-3111.
6. Chakravarty J., Sundar S. Drug resistance in leishmaniasis. J. Glob. Infect. Dis. 2010, 2:167-176.
7. Croft S.L., Sundar S., Fairlamb A.H. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 2006, 19:111-126.
8. Davies C.R., Kaye P., Croft S.L., Sundar S. Leishmaniasis: new approaches to disease control. BMJ 2003, 326:377-382.
9. Fjell C.D., Hiss J.A., Hancock R.E., Schneider G. Designing antimicrobial peptides: form follows function. Nat. Rev. Drug Discov. 2012, 11:37-51.
10. Guy R., Belosevic M. Comparison of receptors required for entry of Leishmania major amastigotes into macrophages. Infect. Immun. 1993, 61:1553-1558.
11. Houimel M., Mach J.P., Corthesy-Theulaz I., Corthesy B., Fisch I. New inhibitors of Helicobacter pylori urease holoenzyme selected from phage-displayed peptide libraries. Eur. J. Biochem. 1999, 262:774-780.
12. Jones B.M., Nicholson J.K., Holman R.C., Hubbard M. Comparison of monocyte separation methods using flow cytometric analysis. J. Immunol. Methods 1989, 125(1-2):41-47.
13. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
14. Laskay T., Diefenbach A., Rollinghoff M., Solbach W. Early parasite containment is decisive for resistance to Leishmania major infection. Eur. J. Immunol. 1995, 25:2220-2227.
15. Laskowski R.A., Swindells M.B. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model 2011, 51:2778-2786.
16. Louzir H., Melby P.C., Ben Salah A., Marrakchi H., Aoun K., Ben Ismail R., Dellagi K. Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. J. Infect. Dis. 1998, 177(6):1687-1695.
17. Meddeb-Garnaoui A., Zrelli H., Dellagi K. Effects of tropism and virulence of Leishmania parasites on cytokine production by infected human monocytes. Clin. Exp. Immunol. 2009, 155(2):199-206.
18. Medina-Acosta E., Karess R.E., Schwartz H., Russell D.G. The promastigote surface protease (gp63) of Leishmania is expressed but differentially processed and localized in the amastigote stage. Mol. Biochem. Parasitol. 1989, 37:263-273.
19. Mor A. Multifunctional host defense peptides: antiparasitic activities. FEBS J. 2009, 276(22):6474-6482.
20. Peters C., Aebischer T., Stierhof Y.-D., Fuchs M., Overath P. The role of macrophage receptors in adhesion and uptake of Leishmania mexicana amastigotes. J. Cell Sci. 1995, 108:3715-3724.
21. Peters N.C., Egen J.G., Secundino N., Debrabant A., Kimblin N., et al. In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science 2008, 321:970-974.
22. Pini A., Giuliani A., Falciani C., Runci Y., Ricci C., et al. Antimicrobial activity of novel dendrimeric peptides obtained by phage display selection and rational modification. Antimicrob. Agents Chemother. 2005, 49:2665-2672.
23. Rao S.S., Mohan K.V., Gao Y., Atreya C.D. Identification and evaluation of a novel peptide binding to the cell surface of Staphylococcus aureus. Microbiol. Res. 2012, 12:S0944-5013.
24. Rathinakumar R., Walkenhorst W.F., Wimley W.C. Broad-spectrum antimicrobial peptides by rational combinatorial design and high-throughput screening: the importance of interfacial activity. J. Am. Chem. Soc. 2009, 131:7609-7617.
25. Rijal S., Chappuis F., Singh R., Bovier P.A., Acharya P., Karki B.M., Das M.L., Desjeux P., Loutan L., Koirala S. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans. R. Soc. Trop. Med. Hyg. 2003, 97:350-354.
26. Seeliger D., de Groot B.L. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J. Comput. Aided Mol. Des. 2010, 24:417-422.
27. Uerin P.J., Olliaro P., Sundar S., Boelaert M., Croft S.L., Desjeux P., Wasunna M.K., Bryceson A.D. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis. 2002, 2:494-501.
28. Wilson M., Pearson R.D. Roles of CR3 and mannose receptors in the attachment and ingestion of Leishmania donovani by human mononuclear phagocytes. Infect. Immun. 1988, 56:363-369.
29. Yao C., Leidal K.G., Brittingham A., Tarr D.E., Donelson J.E., Wilson M.E. Biosynthesis of the major surface protease GP63 of Leishmania chagasi. Mol. Biochem. Parasitol. 2002, 121:119-128.
30. Yao C., Luo J., Storlie P., Donelson J.E., Wilson M.E. Multiple products of the Leishmania chagasi major surface protease (MSP or GP63) gene family. Mol. Biochem. Parasitol. 2004, 135:171-183.
31. Yao C., Luo J., Hsiao C., Donelson J.E., Wilson M.E. Internal and surface subpopulations of the major surface protease (MSP) of Leishmania chagasi. Mol. Biochem. Parasitol. 2005, 139:173-183.
32. van Zandbergen G., Klinger M., Mueller A., Dannenberg S., Gebert A., et al. Cutting edge: neutrophil granulocyte serves as a vector for Leishmania entry into macrophages. J. Immunol. 2004, 173:6521-6525.